颜红兵,霍勇

• 1:中国医学科学院阜外医院深圳医院冠心病中心
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心
• 3:北京大学第一医院心内科

摘要(Abstract)：

<正>尽管他汀类药物能显著降低低密度脂蛋白胆固醇浓度，从而显著减少心血管事件，但冠状动脉粥样硬化性心脏病（冠心病）患者仍存在其他重要的残余心血管风险，例如炎症~([1])。炎症在冠心病的发生、发展和表现中起着关键作用，因此医学界一直在艰辛探索将抗炎治疗在临床上应用于动脉粥样硬化性患者~([2-3])。过去几年，以分别应用卡那单抗、甲氨蝶呤和秋水仙碱的随机双盲安慰剂对照临床试验为代表的研究表明，为预防和治疗动脉粥样硬化临床并发症，靶向抗炎治疗提供了一种有希望的新途径。卡那单抗是单克隆抗体制剂，价格高，并且相关研究较少，目前难以推广。

关键词(KeyWords)： 动脉粥样硬化;冠心病;秋水仙碱;抗炎治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 颜红兵,霍勇

参考文献(References)：

• [1] Libby P. Infl ammation during the life cycle of the atherosclerotic plaque[J]. Cardiovasc Res,2021,117(13):2525-2536.
• [2] Alfaddagh A, Martin SS, Leucker TM,et al. Infl ammation and cardiovascular disease:from mechanisms to therapeutics[J].Am J Prev Cardiol,2020, 4:100130.
• [3] Soehnlein O, Libby P. Targeting infl ammation in atherosclerosis-from experimental insights to the clinic[J]. Nat Rev Drug Discov,2021,20(8):589-610.
• [4] Ridker PM, Everett BM, Thuren T, et al. Antiinfl ammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
• [5] Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
• [6] Tardif JC, Kouz S, Waters DD,et al. E ffi cacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
• [7] Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 trial investigators. colchicine in patients with chronic coronary disease[J].N Engl J Med,2020,383(19):1838-1847.
• [8] Angelidis C, Kotsialou Z,Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action[J]. Curr Pharm Des, 2018, 24(6):659-663.
• [9] Chen K, Schenone AL, Borges N. Teaching an old dog new tricks:colchicine in cardiovascular medicine[J]. Am J Cardiovasc Drugs, 2017, 17(5):347-360.
• [10] Schenone AL,Menon V. Colchicine in pericardial disease:from the underlying biology and clinical benefi ts to the drug-drug interactions in cardiovascular medicine[J]. Curr Cardiol Rep,2018,20(8):62.
• [11] Thompson PL. Colchicine in cardiovascular disease:repurposing an ancient gout drug[J]. Clin Ther, 2019,41(1):8-10.
• [12] Martin?ez GJ, Celermajer DS, Patel S. The NLRP3inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated infl ammation[J]. Atherosclerosis,2018,269:262-271.
• [13] Hansson GK, Klareskog L. Pulling down the plug o n atherosclerosis:cooling down the infl ammasome[J]. Nat Med,2011,17(7):790-791.
• [14] Spagnoli LG, Mauriello A, Orlandi A, et al. Age-related changes affecting atherosclerotic risk[J]. Drugs Aging,1996,8(4):275-298.
• [15] Andreis A, Imazio M, Piroli F, et al. E ffi cacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease:a systematic review and meta-analysis on 12 869 patients[J]. Eur J Prev Cardiol,2022,28(17):1916-1925.
• [16] Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome:the australian COPS randomized clinical trial[J]. Circulation, 2020,142(20):1890-1900.
• [17] Mewton N, Roubille F, Bresson D, et al. Ef fect of colchicine on myocardial injury in acute myocardial infarction[J].Circulation, 2021, 144(11):859-869.
• [18] Shah B, Pillinger M, Zhong H, et al. Effects of a c u t e colchicine administration prior to percutaneous coronary intervention:COLCHICINE-PCI randomized trial[J]. Circ Cardiovasc Interv, 2020, 13(4):e008717.
• [19] Correa-Sadouet C, Rodríguez-Granillo AM, Gallardo C, et al. ORCA investigators. Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention[J]. Future Cardiol,2021,17(4):539-547.
• [20] Opstal TSJ, Fiolet ATL, van Broekhoven A, et al,LoDoCo2trial investigators. colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome[J]. J Am Coll Cardiol,2021, 78(9):859-866.
• [21] Bouabdallaoui N, Tardif JC, Waters DD, et al. Timeto-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial(COLCOT)[J]. Eur Heart J, 2020, 41(42):4092-4099.
• [22] Libby P. Infl ammation in atherosclerosis—no longer a theory[J].Clin Chem, 2021,67(1):131-142.
• [23] Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease:in-depth review[J]. Circulation,2022,145(1):61-78.